Macfarlanes has advised SV Health Investors on the transaction. SV Health Investors raised its first biotech fund, which has closed at its hard cap of $265m….
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
